Clinical Research Directory
Browse clinical research sites, groups, and studies.
Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.
Sponsor: Northwell Health
Summary
Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia. The investigator hypothesizes that Urolift, which represents a novel minimally invasive therapy, may reduce acute and long-term urinary toxicity and side effects of radiation therapy (SBRT).
Official title: Reduction of Urinary Toxicity of Stereotactic Body Radiation Therapy (SBRT) With Prostatic Urethral Lift (Urolift)
Key Details
Gender
MALE
Age Range
50 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-02-11
Completion Date
2028-03
Last Updated
2026-09-29
Healthy Volunteers
Yes
Conditions
Interventions
Urolift
Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
Locations (1)
Northwell Health
Syosset, New York, United States